POPULARITY
Categories
Flor Stella Quiroga, coordinadora del Comité Nacional Gremial de Contadores Públicos, estuvo en 6AM para hablar de la declaración de la DIAN sobre la contingencia en sus servicios informáticos.
O histórico grupo galego Milladoiro actuará este sábado no Teatro Jofre de Ferrol como parte da súa xira conmemorativa de máis de 45 anos nos escenarios. Nesta ocasión, contarán coa colaboración especial da parella formada por Eva Faraldo e Jesús Quiroga, que teñen preparadas varias coreografías para acompañar ao grupo durante o concerto. Eva e Jesús xa participaron o ano pasado no inicio da xira no Palacio da Ópera e teñen colaborado con Milladoiro en numerosas ocasións, achegando o seu talento escénico e reforzando a conexión entre a música tradicional e a danza contemporánea.
Melisa Galvano Quiroga - Programa "Contame que te motivo" - Jueves 8 de Mayo.
07 05 2025 Noticiero Cardinal - Eduardo Quiroga - Gte de Inmobiliaria del Este by ABC Color
Álvaro Quiroga, tesorero de la Asociación de Estudiantes de Enfermería, nos habla de la primera Gala de Enfermería.
In "¿De qué casa eres?" director Ana Perez Quiroga traces the deep scars and resilience shaped by war, displacement, and identity. The post “¿De qué casa eres?”, interview with director Ana Perez Quiroga appeared first on Fred Film Radio.
In "¿De qué casa eres?" director Ana Perez Quiroga traces the deep scars and resilience shaped by war, displacement, and identity. The post “¿De qué casa eres?”, interview with director Ana Perez Quiroga appeared first on Fred Film Radio.
In "¿De qué casa eres?" director Ana Perez Quiroga traces the deep scars and resilience shaped by war, displacement, and identity. The post “¿De qué casa eres?”, interview with director Ana Perez Quiroga appeared first on Fred Film Radio.
In "¿De qué casa eres?" director Ana Perez Quiroga traces the deep scars and resilience shaped by war, displacement, and identity. The post “¿De qué casa eres?”, interview with director Ana Perez Quiroga appeared first on Fred Film Radio.
In "¿De qué casa eres?" director Ana Perez Quiroga traces the deep scars and resilience shaped by war, displacement, and identity. The post “¿De qué casa eres?”, interview with director Ana Perez Quiroga appeared first on Fred Film Radio.
In "¿De qué casa eres?" director Ana Perez Quiroga traces the deep scars and resilience shaped by war, displacement, and identity. The post “¿De qué casa eres?”, interview with director Ana Perez Quiroga appeared first on Fred Film Radio.
Melisa Galvano Quiroga - Programa "Contame que te motivo" - Jueves 1 de Mayo.
Melisa Galvano Quiroga - Programa "Contame que te motivo" -Jueves 24 de abril.
La ciudad de Ferrol se suma a la celebración del Día Internacional de la Danza con una gala especial que se celebrará el domingo 27 de abril de 2025, a las 19:30 h, en el Auditorio Municipal. El evento, organizado por la Concellería de Cultura del Concello de Ferrol en colaboración con diversas escuelas locales, busca poner en valor la danza como arte escénico esencial. Participarán reconocidas academias como Rosa Salanova, Estudio de Danza Paloma, Allegro, Matilde Pedreira, Seven And, Amei, Lago, Comparte y Mundodanza Jesús Quiroga. El espectáculo incluirá una variada muestra de estilos que van desde la danza clásica y contemporánea hasta la urbana y fusiones escénicas. Durante la gala también se hará una breve introducción sobre el origen de esta conmemoración, instaurada por la UNESCO en 1982 en honor a Jean-Georges Noverre, precursor del ballet moderno. Las entradas estarán disponibles desde el 22 de abril en la taquilla del Teatro Jofre y el mismo día del evento en el Auditorio Municipal, hasta completar aforo. Ferrol reafirma así su compromiso con la cultura, celebrando la danza como un lenguaje universal y puente entre culturas.
Melisa Galvano Quiroga - Programa "Contame que te motivo" - Jueves 17 de Abril.
Melisa Galvano Quiroga - Programa "Contame que te motivo" - Jueves 10 de Abril.
Melisa Galvano Quiroga - Programa "Contame que te motivo" - Jueves 3 de Abril.
Hablamos con él sobre los trabajos que está llevando a cabo el equipo técnico de las fosas comunes de Córdoba para localizar a represaliados en el Cementerio de La Salud
En #StockDisponible, se hizo presente "La Cosa Nostra" de la mano de Darío Quiroga y Alberto Mayol, para analizar la encuesta n-25 de "La Cosa Nostra" y ver la brújula política exacta. - ¡Síguenos en todas nuestras plataformas! ➡ https://canalviax.com/ Instagram https://www.instagram.com/canalviax/ TikTok https://www.tiktok.com/@canalviaxoficial Facebook https://www.facebook.com/canalviax Twitter https://www.twitter.com/viax
Melisa Galvano Quiroga - Programa "Contame que te motivo" - Jueves 27 de marzo.
ENTREVISTA A BORJA QUIROGA1. IntroducciónBienvenido, Borja, un placer tenerte aquí. Antes de entrar en materia, cuéntanos un poco sobre ti y qué te llevó a escribir Por mis riñones que hoy como bien.2. La importancia de los riñonesPodríamos decir que los riñones son la depuradora del organismo… quien depura entonces hígado o riñón? Hay que depurar la depuradora?Empecemos por lo básico: ¿qué papel juegan los riñones en nuestro cuerpo y por qué son tan esenciales para nuestra salud?En el libro hablas de klotho como el elixir de la juventud, a qué te refieres exactamente? Podríamos suplementarnos con ella?Es curioso que podamos vivir con un solo riñón. ¿Cómo es posible que uno solo sea suficiente?¿Crees que la gente es consciente de la importancia de cuidar sus riñones o es un órgano al que se le presta poca atención?¿Cuál es el mayor error que comete la gente en su dieta cuando se trata de cuidar los riñones?¿Qué consejos prácticos daríais a alguien que quiere empezar a cuidar sus riñones hoy mismo?3. Riñones enfermos¿Qué signos o síntomas pueden ayudarnos a sospechar de que nuestros riñones están dañados?Solemos prestar mucha atención a la orina solo cuando cambia de color o de olor. ¿Qué información nos puede dar el pipí sobre nuestra salud?¿Cuántas veces al día deberíamos ir al baño para considerar que tenemos un hábito urinario saludable? ¿Tiene consecuencias o riesgos aguantar las ganas de orinar?¿Es importante también el número de veces que voy a orinar y cuánto orino?Hay personas que beben mucho líquido pero orinan poco. ¿Puede ser un signo de que algo no funciona bien?¿Qué es y qué no es la retención de líquidos? Cómo saber si la tengo? Alimentación en la retención de líquidos.¿Cuando hay retención de líquidos, debemos beber más agua o menos?4. Patología renalEmpecemos por lo menos grave…Cistitis, Alimentación en la cistitis.¿Hay evidencia de que consumir arándanos previene la cistitis? y de que la trata? Porque hay tanta resistencia al Monurol?Litiasis renal, uno de los problemas renales más comunes son los cálculos renales. ¿Por qué se forman?En el libro aclaras que no es lo mismo la alimentación en la prevención de la litiasis que en el tratamiento, en cuanto al consumo de agua, podrías explicarnoslo?¿Qué podemos hacer dieteticamente hablando para expulsar una piedra? Depende del tamaño? ¿Qué otras consideraciones deberíamos tener en la alimentación en litiasis?.Se dice que el calcio forma las piedras en el riñón, pero al mismo tiempo se recomienda una alimentación rica en calcio. ¿Cómo se explica esta contradicción?En el libro desmientes algunos mitos sobre la litiasis renal. ¿Podrías explicarnos algunos de los más extendidos?Insuficiencia renal. Alimentación en la IR.¿Qué relación hay entre la hipertensión arterial y la salud renal? En tu libro hablas sobre la relación entre el daño renal y la diabetes tipo 2. ¿Por qué la diabetes es una de las principales causas de insuficiencia renal?La diabetes insípida es una enfermedad poco conocida. ¿Podrías explicarnos en qué consiste y por qué afecta a la función renal? Alimentación en la diabetes insípida.5. Hidratación y salud renalLos de los 2L de agua al día… ¿Cuánta agua deberíamos beber al día realmente? ¿Depende de la persona y la situación?En el deporte, la hidratación es clave. ¿Cómo deben hidratarse correctamente los deportistas?El alcohol es líquido, pero ¿hidrata o deshidrata?6. Alimentación y salud renal¿Cuál sería la alimentación preventiva de la patología renal?Después de todo lo que hemos hablado, podemos concluir que loos nutrientes clave en la salud renal son las proteínas, el sodio (o la sal), el potasio, el magnesio y el fósforo. ¿Crees que a los pacientes les resulta complejo adecuar su alimentación a las recomendaciones dadas según daño renal?¿Podemos comer riñones?7. Suplementos y salud renal¿Son peligrosos los suplementos de calcio automedicados? ¿Y los de magnesio?¿Y qué hay de los de vitamina D?En cuanto a los suplementos de proteína…¿Hay riesgo al consumirlos? Quién debería y quién no debería tomarlos?La creatina es un suplemento muy popular entre deportistas, pero existe la creencia de que daña los riñones. ¿Es esto cierto? ¿La creatina es inocua para todos?8. Ayuno y salud renalSé que eres un defensor del ayuno. ¿Qué beneficios tiene para la función renal y la salud en general? 9. CierrePara terminar, ¿Qué mensaje clave os gustaría que los lectores se llevaran después de leer este libro y qué mensaje te gustaría dejar a quienes nos escuchan sobre la importancia de cuidar sus riñones?¿Dónde pueden encontrar tu libro y seguir tu trabajo?Conviértete en un seguidor de este podcast: https://www.spreaker.com/podcast/comiendo-con-maria-nutricion--2497272/support.
Melisa Galvano Quiroga - Programa "Contame que te motivo" - Jueves 20 de marzo.
Join Peggy Hoyt as she chats with Paulette Quiroga-Jacklin, founder of Healing Hearts Donkey Shelter and Refuge. Discover the critical components of responsible donkey ownership. Hear how Paulette is transforming the lives of donkeys through rescue, rehabilitation, training, and facilitating adoptions.Support the show
El nombramiento de Julián Flórez Quiroga en la cartera de Minas estaría en vilo
Sección presentada por Portal Vendedor, dedicada a los motoviajeros y su pasión por salir a la ruta, recorrer y descubrir caminos y lugares.
La directora del Teatro de la Zarzuela, Isamay Benavente, nos presenta la nueva edición del Proyecto Zarza. En el apartado de Libretistas de zarzuela, escuchamos obras de Alonso y Quiroga, con libreto de José López de Lerena.Escuchar audio
For the March 2025 edition of Cultural workers for Palestine I am sharing a conversation with Ana Quiroga, a London based sound artist and musician. Ana's experimental work explores different sonic landscapes and cultural identities as expressed in sound. Ana speaks, in this interview, about experiences joining protest movements in both Spain and London, going back to the mass protests against the U.S. driven invasion of Iraq in 2003, to the M8 protests for gender equality in Spain and the recent wave of solidarity actions for Palestine. Learn more about Ana's work here: https://www.anaquiroga.net This interview series hosted by Stefan Christoff airs on the first Monday of each month on Radio AlHara at 5:30pm, Palestine time, 10:30am eastern time. Also this series airs on CKUT 90.3 FM on the third Friday of each month at 11:30am on Jan. 17, 2025. To listen in on Radio AlHara visit : radioalahra.net
En #StockDisponible, se hizo presente "La Cosa Nostra" de la mano de Darío Quiroga y Alberto Mayol, para analizar la encuesta N° 24 de "La Cosa Nostra" y ver la brújula política exacta.
In unserem neuen Podcast-Format sprechen die „DONE DEALS“-Hosts Fabian Knottnerus und Lennart Gens über fast vergessene Bundesliga-Stars aus den letzten 25 Jahren. Wir gehen das Alphabet von A-Z durch und stellen euch jeden Tag einen besonderen Spieler vor. Mit dabei sind Kultspieler, zwischenzeitliche Leistungsträger und viele weitere. Weiter geht es mit dem Buchstaben Q und Facundo Quiroga.
Este programa está patrocinado por FIND YOUR EVEREST. Puedes conocer todos los productos aquí: https://findyoureverest.es/ En este episodio del Find Your Everest Podcast by Javi Ordieres: - Hablamos con Blas, director de carrera de Quiroga Trail Challenge. - Analizamos la hazaña de Mathieu Blanchard en el Yukon Artic Ultra - Wikiloc y Coros, ya se pueden vincular. - Repasamos las carreras de 100 millas en España. En la sección de PRÓXIMAS CARRERAS, analizamos todas las carreras que vendrán en estas próximas semanas de la mano de la app RUNNUN: https://runnun.app/ En la sección del “Experto responde” hablamos con el nutricionista PABLO EGUEN. Puedes contactar con Pablo en: https://www.pabloeguennutricion.com/ En la sección material, Richar nos hace un repaso de los top ventas este pasado mes. Y para cerrar el programa, en la sección de encuesta, vemos que tipo de geles, son los más elegidos! ESPERO QUE OS GUSTE EL PROGRAMA QUE HEMOS PREPARADO! Ya sabéis que podéis apoyarnos, visitando nuestra tienda online de Trail Running en: https://www.findyoureverest.es/ Suscríbete a nuestra newsletter: https://findyoureverest.es/newsletter/
NotiMundo A La Carta - Diego Quiroga, Acciones De Seguridad Para Las Elecciones Generales 2025 by FM Mundo 98.1
Invité a la cheve al alcalde de Cienega de Flores, un municipio de mucha tradición en mi estado Nuevo León.Aprendí mucho de esta cheve y quiero que la vean!! Está bien entretenida, no es nada fácil esto de ser alcalde!
Dr. Jasmine Sukumar and Dr. Dionisia Quiroga discuss advances in adjuvant therapy for patients with early breast cancer and BRCA1/2 mutations, including how to identify patients who should receive genetic testing and the significant survival benefits of olaparib that emerged from the OlympiA trial. TRANSCRIPT Dr. Jasmine Sukumar: Hello, I'm Dr. Jasmine Sukumar, your guest host of the ASCO Daily News Podcast today. I'm an assistant professor and breast medical oncologist at the University of Texas MD Anderson Cancer Center. On today's episode, we'll be exploring advances in adjuvant therapy for high-risk early breast cancer in people with BRCA1/2 germline mutations. Joining me for this discussion is Dr. Dionisa Quiroga, an assistant professor and breast medical oncologist at the Ohio State University Comprehensive Cancer Center. Our full disclosures are available in the transcript of this episode. Dr. Quiroga, it's great to have you on the podcast. Thanks for being here. Dr. Dionisia Quiroga: Thank you. Looking forward to discussing this important topic. Dr. Jasmine Sukumar: Let's start by going over who should be tested for BRCA1/2 genetic mutations. How do you identify patients with breast cancer in your clinic who should be offered BRCA1/2 genetic testing? Dr. Dionisia Quiroga: So, guidelines on who to offer testing to somewhat differ between organizations at this point. I would say, generally, I do follow our current ASCO-Society of Surgical Oncology (SSO) Guidelines, though. Those guidelines recommend that BRCA1/2 mutation testing be offered to all patients who are diagnosed with breast cancer and are 65 years old or younger. For those that are older than 65 years old, there are additional factors to really take into account to decide on who to recommend testing for. Some of this has to do with personal and family history as well as ancestry. The NCCN also has their own specific guidelines for who to offer testing to. For example, people assigned male at birth; those who are found to have a second breast primary; those who are diagnosed at a young age; and those with significant family history should also be offered BRCA1/2 testing. I think, very important for our discussion today, ASCO and SSO also made a very important point that all patients who may be eligible for PARP inhibitor therapy should be offered testing. So clearly this includes a large amount of our patient population. In my practice, we often refer to our Cancer Genetics Program. We're fortunate to have many experienced genetic counselors who can complete pre-test and post-test counseling with our patients. However, in settings where this may not be accessible to patients, it can also be appropriate for oncology providers to order the testing and ideally perform some of this counseling as well. Dr. Jasmine Sukumar: Thank you Dr. Quiroga. Let's next review where we are in current clinical practice guidelines. What current options do we have for adjuvant therapy specific to people with high-risk early breast cancer and BRCA1/2 genetic mutations? Dr. Dionisia Quiroga: Our current guidelines recommend adjuvant olaparib for one year for individuals with HER2-negative high risk breast cancer. This approval largely came from the data and the results of the OlympiA trial. This was a prospective phase 3, double blind, randomized clinical trial. It enrolled patients who had been diagnosed with HER2-negative early-stage breast cancer who also carried germline pathogenic or likely pathogenic variants of either the BRCA1 and/or BRCA2 genes. The disease also had to be considered high-risk and there were several criteria that had to be evaluated to deem whether or not these patients were high-risk. For example, those who are treated with neoadjuvant chemotherapy, if they had disease that was triple-negative, they needed to have some level of invasive residual disease at time of surgery. Alternatively, if the disease was hormone receptor-positive, they needed to have residual disease and a calculated CPS + EG score of 3 or higher. This scoring system is something that estimates relapse probability on the basis of clinical and pathologic stage, ER status, and histologic grade, and this will give you a score ranging from 0 to 6. In general, the higher the score, the worse the prognosis. This calculator though is available to the public online to allow providers to calculate this risk. For the subset of patients who received adjuvant chemotherapy, for them to qualify for the OlympiA trial, if they had triple-negative disease, they needed to have a tumor of at least 2 cm or greater and/or have positive lymph nodes for disease. For hormone receptor-positive disease that was treated with adjuvant chemotherapy, they were required to have four or more pathologically confirmed positive lymph nodes at time of surgery. From this specified pool, patients were then randomized 1:1 to get either adjuvant olaparib starting at 300 mg twice a day or a matching placebo twice a day after they had completed surgery, chemotherapy and radiation treatment if needed. Dr. Jasmine Sukumar: And what were the outcomes of this study? Dr. Dionisia Quiroga: The study ended up enrolling over 1,800 patients and from these 1,800 patients, 70% had a BRCA1 mutation while 30% had a BRCA2 mutation. About 80% of the patients had triple-negative disease compared to hormone receptor-positive disease. Interestingly, about half of all patients enrolled had received neoadjuvant chemotherapy while the other half received adjuvant chemotherapy. Looking at the outcomes, this was overall a very positive study. We actually now have outcomes data from a median of about 6 years out. This was just reported in December at the 2024 San Antonio Breast Cancer Symposium. There was found to be a 9.4% absolute difference in six-year invasive disease-free survival favoring the olaparib arm over the placebo arm. What was also interesting is that this was consistent across multiple subgroups of patients and the benefit was really seen whether or not they had hormone receptor-positive or triple-negative disease. The absolute difference in distant disease-free survival was also high at 7.8% and additionally favored olaparib. Most importantly, there was found to be a significant overall survival benefit. The six-year overall survival was 87.5% in the olaparib group compared to 83.2% in the placebo group. This translates to about a 4.4% difference and a relative 28% overall survival benefit in using olaparib. Now, future follow up is going to be very important. Follow up for this study is actually planned to continue out until June 2029 so we can continue to observe if these survival curves will continue to branch apart as they have so far at each follow up. And I think this is especially important for those patients diagnosed with hormone receptor-positive cancers because we know those patients are at particular risk for later recurrences. As an additional side note, the researchers also noted that there were fewer primary malignancies in the olaparib group, not just of the breast but also primary ovarian or fallopian tube cancers as well, which is not completely surprising knowing that this drug is also heavily used and beneficial in different types of gynecologic cancers. Ultimately, the amount of adverse events reported have been low with only about 9.9% of patients receiving olaparib needing to discontinue drug due to adverse events, and this is compared to 4.2% reported in the placebo group. Dr. Jasmine Sukumar: You mentioned that the OlympiA trial showed an overall survival benefit, but interestingly the OlympiAD trial looking at olaparib versus chemotherapy in patients with advanced metastatic HER2-negative breast cancer did not show a significant overall survival benefit. Could you discuss those differences? Dr. Dionisia Quiroga: I agree, that's a very good point. So OlympiA's comparator arm was, of course, a placebo. So while this isn't the same as comparing to chemotherapy, it does still potentially suggest that there is a degree of benefit that olaparib can provide when it's introduced in the early local disease setting compared to advanced metastatic disease. I think we need more future trials looking at potential other combinations to see if we can improve the efficacy of PARP inhibitors in the metastatic setting. Dr. Jasmine Sukumar: For patients who do choose to proceed with use of adjuvant olaparib due to the promising efficacy, what side effects should oncologists counsel their patients about? Dr. Dionisia Quiroga: The most common notable side effects, I would say with olaparib and other PARP inhibitors are really cytopenias. Gastrointestinal side effects such as nausea and vomiting can occur as well as fatigue. There are some less common but potentially more serious side effects that we should counsel our patients on. This includes pneumonitis. So counseling patients on if they're short of breath or experiencing cough to let their provider know. Venous thromboembolism can also be increased rates of occurrence. And then of course myelodysplastic syndromes or acute myeloid leukemia is something that we often are concerned about. That being said, I think it should be noted that interestingly in the OlympiA trial so far, there have been less new cases of MDS and AML in the olaparib group than actually what's been reported in the placebo group at this median follow up of over six years out. So we'll need to continue to monitor this endpoint over time, but I do think this provides some reassurance. Dr. Jasmine Sukumar: Since the initiation of the OlympiA trial, other adjuvant treatments have also been studied and FDA approved for non-metastatic HER2-negative breast cancer. So for example, the CREATE-X trial established adjuvant capecitabine as an FDA approved treatment option in patients with triple-negative breast cancer who had residual disease following neoadjuvant chemotherapy. So if a patient with triple-negative breast cancer with residual disease is eligible for both adjuvant olaparib and adjuvant capecitabine treatments, how do you decide amongst the two? Dr. Dionisia Quiroga: If a patient's eligible for both, I honestly often favor olaparib, and I do this because I find the data for adjuvant olaparib a little bit more compelling. There are also differences in toxicity profile and treatment duration between the two that I think we should discuss with patients. For example, olaparib is supposed to be taken for a year total, whereas with capecitabine we typically treat for six to eight cycles with each cycle taking three weeks. There are some who may also sequence the two drugs in very high-risk disease. However, this is very much a data free zone. We don't have any current clinical trials really comparing these two or if sequencing of these agents is appropriate. So I don't currently do this in my own clinical practice. Dr. Jasmine Sukumar: Nowadays, almost all patients with stage 2 to 3 triple-negative breast cancer will be offered neoadjuvant chemotherapy plus immune checkpoint inhibitor therapy pembrolizumab per our KEYNOTE-522 trial data. With our current approach, pembrolizumab is continued into the adjuvant setting regardless of surgical outcome, so that patients receive a year total of immunotherapy. So in patients with residual disease and a BRCA germline mutation, do you suggest using adjuvant olaparib concurrently with pembrolizumab? Do we have any data to support that approach? Dr. Dionisia Quiroga: I do. I do use them concurrently. If a patient is eligible for adjuvant olaparib, I would use it the same way as if they were not on pembrolizumab. That being said, there are no large studies currently that have shown what the benefit or the toxicity of pembrolizumab plus olaparib are for early-stage disease. However, we do have some safety data of this combinatorial approach from other studies. For example, the phase 2/3 KEYLYNK-009 study showed that patients with advanced metastatic triple-negative breast cancer who were receiving concurrent pembrolizumab and olaparib had a manageable safety profile, particularly as the toxicities of these drugs alone don't tend to overlap. Dr. Jasmine Sukumar: And what about endocrine therapy for those that also have hormone receptor-positive disease? Dr. Dionisia Quiroga: Adjuvant endocrine therapy should definitely be continued while patients are on olaparib if they're hormone receptor-positive. An important component of this will also likely be ovarian suppression, which should include recommendation of risk reducing bilateral salpingo oophorectomy due to the risk of ovarian cancer development in patients who carry BRCA1/2 gene mutations. In most cases, this should happen at age 40 or before for those that carry a BRCA1 mutation, and at age 45 or prior for those with BRCA2 mutations. Dr. Jasmine Sukumar: And do you also consider adjuvant bisphosphonates in this context? Dr. Dionisia Quiroga: Yes. Like adjuvant endocrine therapy, adjuvant bisphosphonates were also instructed to be given according to standard guidelines in the OlympiA trial, so I would recommend use of bisphosphonates when indicated. You can refer to the ASCO Ontario Health Guidelines on Adjuvant Bone-Modifying Therapy Breast Cancer to guide that decision in order to utilize this due to multiple clinical benefits. It doesn't just help in terms of adjuvant breast cancer treatment but also reduction of fracture rate and down the line, improved breast cancer mortality. Dr. Jasmine Sukumar: Particularly in hormone receptor-positive breast cancer, another adjuvant therapy option that was not available when the OlympiA trial started are the CDK4/6 inhibitors, ribociclib and abemaciclib, based on the NATALEE and monarchE studies. So how do you consider the use of these adjuvant therapy drugs in the context of olaparib and BRCA mutations? Dr. Dionisia Quiroga: Yeah, so we are definitely in a data-free zone here. And that's in part because the NATALEE and the monarchE studies are still ongoing and reporting data out at the same time that we're getting updated OlympiA data. So unlike some of our other adjuvant treatments that we discussed, where olaparib could be safely given concurrently, the risk of myelosuppression and using both a CDK4/6 inhibitor and a PARP inhibitor at the same time would be too high. In some cases, even if a patient has a BRCA1/2 mutation, they may not meet that specified inclusion criteria that OlympiA set for what they consider to be high-risk disease. And we know from the NATALEE and the monarchE trial there are also different markers that they use to denote high-risk disease. So it's possible, for example, in the NATALEE trial that looks specifically at adjuvant ribociclib, they included a much larger pool of hormone receptor-positive early-stage breast cancers, including a subset that did not have positive axillary lymph nodes. In cases where patients would qualify for both olaparib and a CDK4/6 inhibitor, I think this is worth a nuanced discussion with our patients about the potential benefits, risks and administration of these drugs. I think another point to bring up is the cost associated with these drugs and the length of time patients will be on for, because financial toxicity is always something that we should bring up with patients as well. When sequencing these in high-risk disease, my practice is to generally favor olaparib first due to the overall survival data. There is also some data to support that patients with BRCA1/2 germline mutations may not respond quite as well to CDK4/6 inhibitors compared to those without. But again, this is still outside of the purview of current guidelines. Fortunately, we have more potential choices for patients, and that's a good thing, but shared decision making also needs to be key. Dr. Jasmine Sukumar: And while our focus today is on adjuvant treatment for people who carry germline BRCA mutations, what about other related gene mutations such as PALB2 pathogenic variant? Dr. Dionisia Quiroga: That's a great question. Clinical trials in the advanced metastatic setting have shown that there is efficacy of olaparib in the setting for PALB2 mutations. This is largely based on the TBCRC 048 phase 2 trial and that provided a Category 2B NCCN recommendation for patients with these PALB2 gene mutations. However, we're really still lacking enough clinical data for use in early-stage disease, so I don't currently use adjuvant olaparib in this case. I am definitely eager for more data in this area as the efficacy of PARP inhibitors in PALB2 gene mutations is very compelling. I think also, in the same line, there's been some data for somatic BRCA1/2 mutations in the metastatic setting, but we still have a lack of data for the early stage setting here as well. Dr. Jasmine Sukumar: Thank you Dr. Quiroga, for sharing your valuable insights with us today on the ASCO Daily News Podcast. Dr. Dionisia Quiroga: Thank you, Dr. Sukumar. Dr. Jasmine Sukumar: And thank you to our listeners for your time today. You'll find links to the studies discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Dionisa Quiroga @quirogad @quirogad.bsky.social Dr. Jasmine Sukumar @JasmineSukumar @jasmine.sukumar.bsky.social Follow ASCO on social media: @ASCO on X @ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Dionisia Quiroga: No relationships to disclose Dr. Jasmine Sukumar: Honoraria: Sanofi (Immediate Family Member)
En #StockDisponible, se hizo presente "La Cosa Nostra" de la mano de Darío Quiroga y Alberto Mayol, para analizar la encuesta n-23 de "La Cosa Nostra" y ver la brújula política exacta.
Platicamos con Fer Quiroga sobre el arte de encontrar el balance para tener una vida exitosa siendo congruente con tus valores y principios. Cómo vivir para ti para poder estar para los demás. Una platica super rica que nos lleva a ver otras perspectivas para quitarle el disfraz al ego y realmente vivir una vida plena. Te comparto donde encontrar a Fer: IG @ferquirogaf , su libro El Arte Del Balance , sus cursos de Balance Hormonal y los mejores suplementos.Registra tu compra aquí antes del 7 de febrero y aprovecha estos regalos:Curso virtual práctico de meditación para conectar con lo intangible.Guía imprimible para aplicarte con tus nuevos hábitos.Evento virtual de lanzamiento.Amo saber lo que mueven los episodios en ti… mándame un mensaje por IG en @mujerconcalma o déjame tus preguntas o comentarios aquí abajo. Por acá puedes ver talleres y cursos disponibles online y presenciales. Y si eres mega fan del podcast o resuena demasiado todo lo que digo, te recomiendo ampliamente unirte a la Comunidad con calma y vernos en vivo cada semana con contenido increíble. Y por supuesto..., nos vemos todas las semanas con una dosis de espiritualidad con los pies en tierra, para que conectes con el gozo y experimentes tu vida llena de éxito y plenitud.
Desde el Teatro Municipal de San Joaquín, Alberto Mayol y Darío Quiroga, hacen LA COSA NOSTRA EN VIVO. Acompañados de Freddy Stock, Valeria Cárcamo, Nicolás Copano y Alejandra Matus. Te esperamos la próxima semana 24 y 25 de enero en el seminario más deseado: LAS 50 LEYES DEL PODER DEL PADRINO / APLICADAS AL 2024. También la premiación de LOS PADRINO AWARDS: https://www.seminarioslacosanostra.cl/producto/13682/50-leyes-del-poder-aplicadas
Francisca Huerta; Nicolás Copano y Darío Quiroga conversaron con Alberto Mayol, analista político, sobre los posibles escenarios que puede traer las elecciones presidenciales 2025.
Federico e Isabel entrevistan al Dr. Borja Quiroga que ha publicado junto al cocinero Miguel Cobo este libro.
Mix of the Week #566 is by Quiroga Latest EP "French Kiss": https://hellyeahrec.bandcamp.com/album/french-kiss Interview: https://www.dreamchimney.com/interviews/quiroga/
Fin de año está a la vuelta de la esquina y en Stock Disponible junto a Darío Quiroga y Alberto Mayol de "La Cosa Nostra", presentamos los premios para los personajes más destacados del año 2024 y sus diferentes categorías.
El precandidato presidencial de Unidad Nacional, Samuel Doria, habló en entrevista con Fernando Del Rincón sobre las declaraciones que dio el expresidente de Bolivia Jorge "Tuto" Quiroga acerca de que él será el candidato “irreversible” del bloque opositor que busca enfrentarse al Movimiento al Socialismo en las elecciones de 2025. Doria destacó la importancia de la unidad en el bloque y aseguró que se mantiene optimista con respecto a lo que pueda ocurrir en los comicios en Bolivia. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Un breve repaso al catálogo discográfico de la etiqueta independiente Puchito del año 1959 nos recuerda el álbum "Cosas de mi Cuba" y la excelencia del cantante Nelo Sosa con la reconocible sonoridad del veterano Conjunto "Gloría Matancera". La agrupación sonera fundada por los hermanos Díaz, con más de 30 años de presencia en los salones bailables, apostaba entonces por un selecto repertorio donde Nelo, con su habitual maestría, logró pasearse por géneros tan diversos y cubanos como la guajira, la guaracha, el bolero, el guaguancó y el son montuno. Nelo Sosa, una de las voces legendarias de la música popular cubana, luego de grabar sus primeros discos con el Conjunto Casino fundaba en 1946, junto a Senén Suárez, el Conjunto "Colonial". Unos minutos más con Nelo y algunos de sus éxitos con el "Colonial". La era de oro de las victrolas en Cuba y el rastro de una de las vertientes del bolero, nos permiten regresar a los catálogos discográficos Panart, RCA Víctor y Velvet. No pocos intérpretes cubanos y extranjeros introdujeron el bolero moruno en sus repertorios. En las victrolas de la isla la oportuna fórmula de la traición, el desengaño amoroso, el despecho y el alcohol por supuesto que les dió un toque muy especial. Domingo Lugo con el Conjunto "Club", Barbarito Diez con la orquesta de sus grandes triunfos: Antonio María Romeu y Julio Valdés con el conjunto del pianista, arreglista y compositor Severino Ramos, protagonizan los primeros minutos de este segmento con algunos boleros morunos de autoría cubana. Como complemento de aquella peculiar banda sonora donde tuvo especial presencia el bolero moruno, también destacaron muchas piezas de compositores españoles "cubanizadas" en todos los marcos musicales posibles desde los jazz bands, pasando por los conjuntos, las orquestas típicas y las agrupaciones de clave y guaguancó. "El día que nací yo", clásico español de Mostazo, Quiroga y Guillén a la manera de Merceditas Valdés con Papin y sus rumberos le da paso a "Te lo juro yo", original del trío autoral Mostazo, León y Quiroga, en versión registrada en discos RCA Víctor por Roberto Espí con el Conjunto Casino de 1946. Le sigue Orestes Macías con otro clásico español. "La bien pagá", de Mostazo y Perelló. Producción de la etiqueta independiente Velvet del año 1960. "Un amigo mío", de la trilogía autoral Naranjo, Murillo y Rivas, concebida originalmente como "zambra habanera", fue un éxito victrolero en el estilo de Orlando Vallejo con el Conjunto de Roberto Faz en discos Panart. Algo de la obra del contrabajista Israel "Cachao" López, traducida en una extensa trayectoria artística en los escenarios de todo el mundo, difundiendo la música cubana y en especial el llamado "danzón de nuevo ritmo", la criatura bailable que creara, junto a su hermano Orestes López, siendo parte ambos de la orquesta del flautista Antonio Arcaño a finales de los años 30 del siglo XX. Cachao López, en dos tiempos: a comienzos de los años 60, con el apoyo del sello del pianista Ernesto Duarte, daba a conocer sus "Super danzones" y, más de 30 años después, radicado en los Estados Unidos mediando los 90s, demostraba estar en plena forma con las hoy clásicas "Master sessions". Edición Sony Music del año 1994 producida por el actor cubano Andy García. Los tesoros de la música popular cubana, los reservamos aquí para ti. Volvemos a las producciones de Jesús Goris con su etiqueta "Puchito" propiciando el debut discográfico de dos importantes referentes de la rumba y el guaguancó: La trilogía inolvidable de Saldiguera, Juan y Virulilla con el "Grupo Guaguancó Matancero" y "Papin y sus rumberos" con Fuico en el apartado vocal. En la despedida uno de los más grandes rumberos cubanos de todos los tiempos: Carlos Embale con el coro de Clave y Guaguancó "Los roncos chiquitos" bajo la conducción del gran Rafael Ortiz "Mañungo".
En una nueva edición del Rat Pack de Mesa Central, Iván Valenzuela conversó con las editoras Carmen Gloria López y Paula Comandari sobre el homicidio de un CEO de la aseguradora UnitedHealthcare en Manhattan y las acusaciones de estafa contra Isidoro Quiroga en la venta de la empresa Australis.
En este episodio, los abogados Héctor y María Quiroga narran el caso de Mariela, una joven venezolana enfrentando amenazas políticas y en busca de Asilo Político. A través de su relato, exploran cómo el consejo personal con base en la mirada holística del caso, a menudo supera en importancia al asesoramiento legal estricto, destacando el valor de la empatía y el apoyo personal en la práctica legal de inmigración. La historia de Mariela resalta la importancia de mantener la esperanza y la persistencia frente a adversidades legales y personales.
Un episodio que busca entender los enfoques de desinformación detrás de la muerte de Juan Felipe Rincón. "Colombia sigue el minuto a minuto del caso del asesinato de Juan Felipe Rincón Morales, hijo del inspector general de la Policía Nacional, William Rincón. Juan Felipe, de 21 años, murió en la mañana del pasado domingo en el barrio Quiroga, al sur de la capital. Allí fue citado por la familia de una menor de ocho años con la que, según denuncian esos familiares, el joven mantenía conversaciones de carácter s3xual"Sara Trejos y Andrés PáramoPost: Rodrigo Rodriguez y Sara TrejosSillón Estudios. Compra tu entrada al presunto cumbión acá: https://presunto.co/tienda/Juan Felipe Rincón: Los extraños hechos que rodean la muerte del hijo del inspector de la policía nacional | EL PAÍS América Colombia Juan Felipe Rincón: Un juez deja libre al único capturado por el asesinato del hijo del inspector de la Policía de Colombia I El PaísEstos son los nuevos videos del asesinato de Juan Felipe Rincón, que juez rechazó: ¿por qué? I NoticiasCaracol “¿Qué hace una niña de 8 años con Instagram?”: Dina Morales, madre de Juan Felipe Rincón I WRadioMadre de Juan Felipe Rincón revela que su hijo fue suplantado en redes: "Le tendieron una trampa"I FMREVELACIONES: Madre de la joven que chateó con Juan Felipe Rincón I Las entrevistas de Julio Sánchez CristoGeneral Rincón podría ser reconocido cómo víctima en caso por el homicidio de su hijo, Juan Felipe I Caracol RadioAsesinato de Juan Felipe Rincón reabre debates sobre justicia por cuenta propia y la exposición de menores en redes sociales I RTVC NoticiasHallaron ABERRANTES CONVERSACIONES de JUAN FELIPE RINCÓN con menores de edad I El CronistaAsesinato de Juan Felipe Rincón: nueva versión enreda más el caso, ¿lo querían matar? I BluRadio Get bonus content on Patreon Hosted on Acast. See acast.com/privacy for more information.
"La poesía sobre el tiempo; lo crea" dice la escritora chileno-boliviana María soledad Quiroga. Nacida en Chile pero asentada en Bolivia, después de haber vivido en países como México y Argentina es socióloga por la UNAM e historiadora de arte por la Academia de Bellas Artes de Bolivia y literatura por la Universidad Mayor de San Andrés. Tenemos una conversación sobre cómo creció con una vida signada por la violencia y la persecución por las ideas de izquierda de su padre, hasta que fue secuestrado por el gobierno de Perón y después encontrado. Su carrera como escritora va entre la poesía y el relato, siempre en la exploración por el "otro". Tiene una abundante obra que empieza en 1993 con el libro Ciudad Blanca y su último libro es Apuntes en el filo: poesía y tiempo en Tres citas impuntuales: tiempo, poesía y falta, en coedición con Fernando van de Wyngard y Mónica Velásquez. Hace una antologia de poetas bolivianas nacidas después de 1952.
Tony Quiroga is the editor-in-chief of Car and Driver. For the last 18 years, his magazine has rented Virginia International Raceway once a year. They've borrowed the best new fast cars, from hot hatches to exotics. And each time, they've spent three days—normal people, not pro drivers—lapping nonstop, looking for time. Sound like a dream day? A pile of stress? Tony is an old friend of INTC, and he says C/D's “Lightning Lap” event is… both! This show's format rotates weekly, because squirrel. Are we doing a run of guest episodes this fall because it sounded like fun? We are! Related Trivia: Sam and Tony once worked together Car and Driver. Later, they worked together at Road & Track. Then it was C/D again. If time is a flat circle, then car magazines are a… flat skidpad, I guess? This episode was produced by Mike Perlman. ** Who We Are + Spicy Merch: www.ItsNotTheCar.com ** Support It's Not the Car: Contribute on Patreon www.patreon.com/notthecar ** Topic suggestions, feedback, questions? Let us know what you think! INTCPod@gmail.com ** Check out Sam's new book! Smithology: Thoughts, Travels, and Semi-Plausible Car Writing, 2003–2023 ** Where to find us: https://www.instagram.com/intcpod https://www.instagram.com/thatsamsmith/ https://www.instagram.com/j.v.braun/ https://www.instagram.com/rossbentley/ https://rossbentley.substack.com/ https://speedsecrets.com/ ** ABOUT THE SHOW: It's Not the Car is a podcast about people and speed. We tell racing stories and leave out the boring parts. Ross Bentley is a former IndyCar driver, a bestselling author, and a world-renowned performance coach. Jeff Braun is a champion race engineer. Sam Smith is an award-winning writer and a former executive editor of Road & Track magazine. We don't love racing for the nuts and bolts—we love it for what it asks of the meatbag at the wheel. New episodes every Tuesday.
Mattos Filho, Veiga Filho, Marrey Jr. e Quiroga has been a trailblazer in advancing access to justice in Brazil, dedicating its pro bono efforts to some of the most pressing social issues. Their work addresses racial discrimination, women's rights, LGBTQ+ rights, and refugee protection, leaving a profound and lasting impact on both individuals and communities. In 2023 alone, the firm provided approximately 20,000 hours of free legal assistance, handled 270 cases, and engaged over 400 legal professionals. Their comprehensive pro bono practice spans individual case defense, support for civil society organizations, strategic litigation, and impactful partnerships with both national and international entities. In this episode of the Pro Bono Happy Hour podcast, we're joined by Flavia Regina Oliveira, Pro Bono Partner and Partner of Social Impact and Philanthropy, along with Caroline Sena, Litigation Associate in Mattos Filho's 100% Pro Bono Practice Group. Listen to hear more about this inspiring work!
Hector Quiroga is an accomplished immigration attorney and CEO of Quiroga Law Firm. Originally from Colombia, Hector immigrated to the United States in 2000. He has dedicated himself to assisting thousands of undocumented families in improving their quality of life. Hector shares his personal journey and professional expertise on immigration policies to inspire and educate others. His law firm has offices in multiple states and even internationally, reflecting his commitment and success in the field.Episode Summary: Host Myrna Young interviews Hector Quiroga about the crucial elements of current U.S. immigration policy. Hector draws on his rich personal and professional experience to break down complex immigration laws, touching upon topics such as family sponsorship, employment visas, and humanitarian processes. The episode is rich with insights aimed at both providing actionable advice for undocumented families and advocating for broader system reforms.Hector discuss a variety of legal ways to enter and remain in the United States, covering essential immigration concepts like the difference between immediate and non-immediate relatives, the nuances of asylum applications, and avenues for skilled and unskilled workers. As Hector navigates through the complexities of waivers and DACA, listeners gain a comprehensive understanding of the multifaceted nature of U.S. immigration law. Key Takeaways:There are multiple avenues to legally enter the United States, including family sponsorship, employment visas, and humanitarian processes.Asylum can be sought by individuals fearing persecution due to political beliefs, religion, or membership in a particular social group.Waivers exist for various grounds of inadmissibility, such as overstay of visas and past legal troubles, making it essential to seek professional legal advice.Support The Sponsors who Support the Transform Your Mind podcast!RO.CO The Ro Body Program provides access to the most popular weight loss shots on the market. Go to RO.CO/TRANSFORMQuince - Make switching seasons a breeze with Quince's high-quality closet essentials. Go to Quince.com/myrna for free shipping on your order.Science Moms - The Science Moms are a non-partisan group of scientists who are, like many of you, moms. Join us at ScienceMoms.comBetterHelp - Transform Your Mind is sponsored by BetterHelp.Give online therapy a try at Betterhelp.com/TYM and get on your way to being your best self.”Shopify - Go to shopify.com/transform now to grow your businessSee this video on The Transform Your Mind YouTube Channel https://www.youtube.com/@MyhelpsUs/videosTo see a transcripts of this audio as well as links to all the advertisers on the show page https://myhelps.us/Follow Transform Your Mind on Instagram https://www.instagram.com/myrnamyoung/Follow Transform Your mind on Facebookhttps://www.facebook.com/profile.php?id=100063738390977Please leave a rating and review on iTunes https://podcasts.apple.com/us/podcast/transform-your-mind/id1144973094